Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 10/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 10/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.52 |
| ▸ | PRKDC | P78527 | 10/20 | 0.52 |
| ▸ | ABL1 | P00519 | 8/20 | 0.52 |
| ▸ | EGFR | P00533 | 8/20 | 0.52 |
| ▸ | HCK | P08631 | 8/20 | 0.52 |
| ▸ | SRC | P12931 | 8/20 | 0.52 |
| ▸ | MTOR | P42345 | 8/20 | 0.52 |
| ▸ | EPHB4 | P54760 | 8/20 | 0.52 |
| ▸ | KDR | P35968 | 7/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 2/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.47 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.47 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10260251 | 0.81 | PIK3CD (0.52) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL29052149 | 0.78 | ADORA2A (0.49) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL29781034 | 0.78 | ADORA2A (0.49) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL18642024 | 0.78 | NR3C1 (0.40) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL29503435 | 0.78 | SRC (0.50) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL29503436 | 0.78 | SRC (0.50) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL130592 | 0.78 | SRC (0.50) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL15826969 | 0.77 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL14692449 | 0.77 | ABL1 (0.58) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL2961144 | 0.77 | SRC (0.58) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774797-B1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | MERCK PATENT GMBH (DE) | 2025-11-19 | — | — | EP | disclosed |
| US-20250236624-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-24 | — | — | US | disclosed |
| CN-112236429-B | Heteroaryl compounds useful as type II IRAK inhibitors and uses thereof | 默克专利有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-115650985-B | Heterocyclic compounds as RET kinase inhibitors | 癌症研究科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20240116938-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-04-11 | — | — | US | disclosed |
| CN-117561260-A | Heterocyclic compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | MERCK PATENT GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-8598156-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2549868-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20090131457-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131457-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | PIK3CA, JAK3, PDK1 | PIK3CD 7/4885PIK3CA 1/4885PIK3CB 12/4885 |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | PIK3CD 725/4885PIK3CA 459/4885PIK3CB 935/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | PIK3CD 725/4885PIK3CA 459/4885PIK3CB 935/4885 |
| US-20250236624-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, REL, BCR | PIK3CD 472/4885PIK3CA 145/4885PIK3CB 678/4885 |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | IRAK2, IRAK3, IRAK1 | PIK3CD 240/4885PIK3CA 180/4885PIK3CB 200/4885 |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, REL, BCR | PIK3CD 472/4885PIK3CA 145/4885PIK3CB 678/4885 |
| US-20240116938-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, HIPK4, HIPK3 | PIK3CD 372/4885PIK3CA 57/4885PIK3CB 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.